Evidence map›Paper›PMID 40733588›Full record

ReviewViruses2025

Marine Bacteriophages as Next-Generation Therapeutics: Insights into Antimicrobial Potential and Application.

Riza Jane S Banicod, Aqib Javaid, Nazia Tabassum, Du-Min Jo, Md Imtaiyaz Hassan, Young-Mog Kim, Fazlurrahman Khan

Abstract readReview
In one paragraph

Review in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Bacteriophages AgainstViruses · 2026
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Riza Jane S BanicodFisheries Postharvest Research and Development Division, National Fisheries Research and Development Institute, Quezon City 1128, Philippines.ORCID 0009-0006-2641-9290
Aqib JavaidInterdisciplinary Program of Marine and Fisheries Sciences and Convergent Technology, Pukyong National University, Busan 48513, Republic of Korea.
Nazia TabassumMarine Integrated Biomedical Technology Center, The National Key Research Institutes in Universities, Pukyong National University, Busan 48513, Republic of Korea.ORCID 0000-0002-9314-9124
Du-Min JoNational Marine Biodiversity of Korea (MABIK), Seochun 33662, Republic of Korea.ORCID 0000-0002-1257-1463
Md Imtaiyaz HassanCentre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi 110025, India.ORCID 0000-0002-3663-4940
Young-Mog KimMarine Integrated Biomedical Technology Center, The National Key Research Institutes in Universities, Pukyong National University, Busan 48513, Republic of Korea.ORCID 0000-0002-2465-8013
Fazlurrahman KhanInterdisciplinary Program of Marine and Fisheries Sciences and Convergent Technology, Pukyong National University, Busan 48513, Republic of Korea.ORCID 0000-0002-4902-3188

Funding

Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education RS-2023-00241461the Korea Institute of Marine Science & Technology Promotion (KIMST), funded by the Ministry of Oceans and Fisheries RS-2025-02373103
6 · The paper itself

Abstract

Microbial infections are an escalating global health threat, driven by the alarming rise of antimicrobial resistance (AMR), which has made many conventional antibiotics increasingly ineffective and threatens to reverse decades of medical progress. The rapid emergence and spread of multidrug-resistant bacteria have severely limited treatment options, resulting in increased morbidity, mortality, and healthcare burden worldwide. In response to these challenges, phage therapy is regaining interest as a promising alternative. Bacteriophages, the most abundant biological entities, have remarkable specificity toward their bacterial hosts, enabling them to selectively eliminate pathogenic strains. Phage therapy presents several advantages over conventional antibiotics, which include minimal disruption to the microbiome and a slower rate of resistance development. Among the various sources of phages, the marine environment remains one of the least explored. Given their adaptation to saline conditions, high pressure, and variable nutrient levels, marine bacteriophages mostly exhibit enhanced environmental stability, broader host ranges, and distinct infection mechanisms, thus making them highly promising for therapeutic purposes. This review explores the growing therapeutic potential of marine bacteriophages by examining their ecological diversity, biological characteristics, infection dynamics, and practical applications in microbial disease control. It also deals with emerging strategies such as phage-antibiotic synergy, genetic engineering, and the use of phage-derived enzymes, alongside several challenges that must be addressed to enable clinical translation and regulatory approval. Advancing our understanding and application of marine phages presents a promising path in the global fight against AMR and the development of next-generation antimicrobial therapies.

Indexed as

Aquatic OrganismsBacterial InfectionsBacteriophagesPhage TherapySeawaterAnimalsAnti-Bacterial AgentsBacteriaHumansAnti-Bacterial Agentsantimicrobial resistancemarine bacteriophagephage–antibiotic synergyphage cocktailphage-derived enzymesphage therapy

Identifiers

PMID40733588
PMCPMC12300592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.